GPCR
A clean exit, not a gentle trim
Structure Therapeutics is still riding a big stock pop — up 47% — but one holder clearly decided it was time to head for the door. ACT Capital Management sold its entire 38,500-share position in the first quarter, a stake that worked out to roughly $2.63 million based on average Q1 2026 prices.
Why investors should care
A full exit is a louder signal than a routine rebalance. It doesn’t mean the business suddenly broke — funds sell for all kinds of reasons, from portfolio limits to risk management — but it can still land like a tiny thunderclap when a stock has been running hot.
The vibe check
On one hand, Structure Therapeutics has been strong enough to attract serious attention. On the other, when a fund takes the whole table off the bet, the market tends to ask the awkward question: did they see something, or did they just lock in gains?
- ACT Capital Management sold 38,500 shares
- Estimated value of the exit: about $2.63 million
- The stock is still up 47%, so this is happening after a pretty strong run
Big picture: this is more “watch the tape” than “panic button,” but investors in GPCR may want to keep an eye on whether other funds start heading for the exits too.